DAIICHI SANKYO Stock News

AstraZeneca and Daiichi Sankyo have entered into ​a clinical collaboration with ‌Summit Therapeutics to test their cancer drug, Datroway, in ​combination with Summit's ​ivonescimab across multiple tumour types, ⁠including lung and breast ​cancers.

Merck ​and Daiichi ‌Sankyo have ​voluntarily ​withdrawn their ⁠US ​application ​seeking accelerated approval ​for ​their experimental lung ‌cancer ⁠therapy, the ​drugmakers ​said ⁠on Friday.

Malaysia's IHH Healthcare said on Thursday its subsidiary has appealed ​a Tokyo court's dismissal of its damages claim ‌against Daiichi Sankyo over the unit's acquisition of a stake in India's Fortis Healthcare.

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions ...

TOKYO--(BUSINESS WIRE)--The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy or nivolumab monotherapy or enfortumab vedotin plus pembrolizumab) as an adjuvant treatment (after surgery) in patients with muscle invasive urothelial c...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization.

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company's oncology and specialty medicine business through a new globally integrated Commercialization Unit, effective April 1, 2027. As part of the operational excellence pillar outlined in the new Five-Year...